Previous 10 | Next 10 |
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with this Read more ...
Patient Advisory Council to include advocates from the inherited retinal diseases global community New Patient Advisory Council to focus initially on Company ’ s clinical stage programs for X-linked retinitis pigmentosa (XLRP) GAINESVILLE, Fla., and CAMBRIDGE, Mass....
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...
Based on FDA feedback, Applied Genetic Technologies (NASDAQ: AGTC ) has revised the development plan for its gene therapy for X-linked retinitis pigmentosa , an inherited disorder affecting the retina that leads to vision loss. More news on: Applied Genetic Technologies Corporation, H...
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Applied Gen...
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...
Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trial...
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Bionic Sight, LLC announced today that it has dosed the first patient in the Company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forw...
News, Short Squeeze, Breakout and More Instantly...
Applied Genetic Technologies Corporation Company Name:
AGTC Stock Symbol:
NASDAQ Market:
Applied Genetic Technologies Corporation Website:
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has exte...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...